日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

China approves its fourth COVID-19 vaccine for emergency use

By Zhang Zhihao | chinadaily.com.cn | Updated: 2021-03-16 15:05
Share
Share - WeChat
[Photo/Institute of Microbiology of the Chinese Academy of Sciences]

China approved a recombinant protein subunit vaccine against COVID-19 for emergency use on Wednesday, according to the vaccine's developer, the Institute of Microbiology of the Chinese Academy of Sciences. 

So far, the vaccine is the fourth approved by the country for emergency use against COVID-19.

The vaccine was developed by the institute and Anhui Zhifei Longcom Biopharmaceutical. It is currently in phase-three clinical trials in foreign countries including Uzbekistan, Pakistan, Ecuador and Indonesia, with plans to inoculate a total of 29,000 volunteers, the institute said in a statement on Monday.

On March 1, Uzbekistan's Ministry of Innovative Development said it has approved the vaccine for market use in the Central Asian nation under the name ZF-UZ-VAC2001. The vaccine was approved for emergency use in the country on Feb 22, making it the world's first recombinant subunit vaccine to be authorized for clinical use. 

Rather than injecting a whole inactivated pathogen to trigger an immune response like previously approved vaccines, subunit protein vaccines contain purified pieces of the virus's protein to train the immune system. These fragments are incapable of causing disease, thus making this type of vaccines very safe.

Notable subunit vaccines include the vaccine for hepatitis B. This type of vaccine does not require high biosecurity labs to make, has high output and low storage requirements, the institute said.

The vaccine completed phase one and two clinical trials in October, and there were no severe adverse effects recorded, the institute said, adding the protection rate for this vaccine is on par with other COVID-19 recombinant subunit and mRNA vaccines in the world, though it did not disclose efficacy details.

US biotech company Novavax is the maker of another recombinant nanoparticle subunit vaccine for COVID called NVX-CoV2373, whose phase-three trials results released last week showed it was 96.4 percent effective against mild, moderate and severe disease caused by the original COVID-19 strain. The mRNA vaccines, developed by Pfizer and Moderna, both have a protection rate of around 95 percent.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 亚洲天天干 | 日韩影音 | 羞羞视频网站在线观看 | 一区二区三区视频免费 | 亚洲一区二区三区欧美 | 午夜视频网址 | 欧美成人精品 | 99久久久国产精品免费观看 | 日本中文字幕免费 | 狠狠色噜噜狠狠狠狠2018 | 邪不压正免费观看完整高清视频 | 精品国产一区二区国模嫣然 | 天天摸日日干 | 波多野结衣hd在线播放 | 57pao成人永久免费视频 | 五月色网站| 激情丁香开心久久综合 | 久久亚洲国产精品五月天婷 | 999www视频免费观看 | 欧美日韩一区在线观看 | 亚洲午夜精品国产电影在线观看 | 亚洲天天做日日做天天看2018 | 国产成人一区二区 | 天天操一操 | 日本欧美不卡一区二区三区在线 | 免费视频一区 | 色噜噜狠狠色综合欧洲 | 国产精品久久久久久久久久日本 | 美女扒开内裤让男人桶 | 精品亚洲一区二区三区 | 日韩欧美在线观看视频 | 我和我的祖国电影在线观看免费版高清 | 欧美一级欧美三级在线观看 | 婷婷激情综合色五月久久竹菊影视 | 91精品国产高清久久久久久91 | 亚洲精品午夜国产va久久成人 | 毛片在线免费观看完整版 | 日韩不卡在线 | 日本午夜免费无码片三汲大片 | 亚洲午夜剧场 | 精品在线 |